These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. A comparative 2-year study of the effects of sequential regimens of 1 mg 17beta-estradiol and trimegestone with a regimen containing estradiol valerate and norethisterone on the bleeding profile and endometrial safety in postmenopausal women. Koninckx PR; Spielmann D Gynecol Endocrinol; 2005 Aug; 21(2):82-9. PubMed ID: 16294460 [TBL] [Abstract][Full Text] [Related]
11. Continuous transdermal oestrogen and interrupted progestogen as a novel bleed-free regimen of hormone replacement therapy for postmenopausal women. Cameron ST; Critchley HO; Glasier AF; Williams AR; Baird DT Br J Obstet Gynaecol; 1997 Oct; 104(10):1184-90. PubMed ID: 9332998 [TBL] [Abstract][Full Text] [Related]
12. Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study. Samsioe G; Boschitsch E; Concin H; De Geyter C; Ehrenborg A; Heikkinen J; Hobson R; Arguinzoniz M; Ibarra de Palacios P; Scheurer C; Schmidt G; Climacteric; 2006 Oct; 9(5):368-79. PubMed ID: 17080587 [TBL] [Abstract][Full Text] [Related]
13. Endometrial response in estrogen replacement therapy quarterly combined with a progestogen. Boerrigter PJ; van de Weijer PH; Baak JP; Fox H; Haspels AA; Kenemans P Maturitas; 1996 May; 24(1-2):63-71. PubMed ID: 8794436 [TBL] [Abstract][Full Text] [Related]
14. Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian Long Cycle Study Group. Bjarnason K; Cerin A; Lindgren R; Weber T Maturitas; 1999 Aug; 32(3):161-70. PubMed ID: 10515673 [TBL] [Abstract][Full Text] [Related]
15. Low dose transdermal estradiol/norethisterone acetate treatment over 2 years does not cause endometrial proliferation in postmenopausal women. Brynhildsen J; Hammar M Menopause; 2002; 9(2):137-44. PubMed ID: 11875333 [TBL] [Abstract][Full Text] [Related]
16. Five years with continuous combined oestrogen/progestogen therapy. Effects on calcium metabolism, lipoproteins, and bleeding pattern. Christiansen C; Riis BJ Br J Obstet Gynaecol; 1990 Dec; 97(12):1087-92. PubMed ID: 2126198 [TBL] [Abstract][Full Text] [Related]
17. Endometrial cancer after combined hormone replacement therapy. Gruber DM; Wagner G; Kurz C; Sator MO; Huber JC Maturitas; 1999 Mar; 31(3):237-40. PubMed ID: 10340283 [TBL] [Abstract][Full Text] [Related]
18. A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate. Neven P; Lunde T; Benedetti-Panici P; Tiitinen A; Marinescu B; de Villiers T; Hillard T; Cano A; Peer E; Quail D; Nickelsen T; BJOG; 2003 Feb; 110(2):157-67. PubMed ID: 12618160 [TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, multicentre study comparing the clinical effects of two sequential estradiol-progestin combinations containing either desogestrel or norethisterone acetate in climacteric women with estrogen deficiency symptoms. Saure A; Hirvonen E; Milsom I; Christensen A; Damber MG Maturitas; 1996 May; 24(1-2):111-8. PubMed ID: 8794442 [TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest for continuous combined hormone replacement therapy in postmenopausal women. Gräser T; Koytchev R; Müller A; Oettel M Climacteric; 2000 Jun; 3(2):109-18. PubMed ID: 11910651 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]